Form 4: Regeneron EVP Sells Shares Under 10b5-1 Plan

Regeneron Pharmaceuticals' EVP Commercial, Marion McCourt, disposed of 1,021 shares of common stock at $701.51 per share to cover tax withholding obligations.

Summary

• Marion McCourt, EVP Commercial of Regeneron Pharmaceuticals, Inc. (REGN), reported a change in beneficial ownership.
• On December 9, 2025, McCourt disposed of 1,021 shares of common stock.
• The shares were disposed of at a price of $701.51 per share.
• This transaction was marked with code 'F', indicating a disposition to the issuer to satisfy tax withholding obligations.
• The transaction was made pursuant to a Rule 10b5-1(c) plan, which allows insiders to set up a pre-arranged schedule for selling company stock.
• Following this transaction, McCourt directly owns 14,349 shares of common stock and indirectly owns 197 shares through a 401(k) Plan.

Sentiment

Score: 5

Explanation: A Form 4 filing for tax-related disposition is a neutral event. It's a routine transaction and does not inherently indicate positive or negative sentiment about the company's performance or prospects.

Positives

• The transaction was executed under a Rule 10b5-1(c) plan, indicating a pre-scheduled sale not based on new material non-public information.

Negatives

• A disposition of shares by an executive, even for tax purposes, reduces their direct ownership stake in the company.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future outlook.

Industry Context

This is a routine insider transaction filing (Form 4) and does not provide specific insights into broader industry trends or competitive landscape. It reflects an individual executive's stock activity.

Comparison to Industry Standards

• This filing is a standard insider transaction report and does not contain information suitable for comparison to global benchmarks, comparable companies, projects, or results. Such comparisons would typically be found in earnings reports or strategic updates.

Stakeholder Impact

• Shareholders: A minor reduction in an executive's direct ownership, but the transaction is routine and tax-related, so the impact is negligible.
• Employees, Customers, Suppliers, Creditors: No direct impact from this specific transaction.

Next Steps

• This filing does not mention any specific future actions, events, or milestones for the company or the reporting person beyond the reported transaction.

Key Dates

Recommendation

This Form 4 filing reports a routine, pre-scheduled disposition of shares by an executive to cover tax withholding obligations, executed under a Rule 10b5-1 plan. Such a transaction is a neutral event and does not reflect a change in the company's fundamental performance or outlook. Therefore, it does not warrant a change in investment recommendation based solely on this filing.

Keywords

Regeneron Pharmaceuticals, REGN, Marion McCourt, Insider Trading, Form 4, Stock Sale, Tax Withholding, 10b5-1 Plan, Executive Compensation